EVALUATION OF CONTINUOUS GLUCOSE MONITORING (isCGM) ON TYPE 2 DIABETES PATIENTS TREATED WITH BASAL – BOLUS INSULIN THERAPY

Abstract

SUMMARY
 Objective: Evaluate effectiveness of continuous glucose monitoring (isCGM) on type 2 diabetes patients treated with basal – bolus insulin therapy. Method: Descriptive and interventional study on 29 type 2 diabetes patients treated with basal – bolus insulin therapy at Department of Endocrinology and Diabetes, Bachmai Hospital from 1/2023 to 7/2023. Results: Average age is 61.4 ± 17.4. The majority oral antidiabetic drug is Metformin combined with Anti DDP4 (37%), bolus insulin is Regular (73%), basal insulin is Glargine U100 (97%). Average HbA1c is 10,8 ± 2,8 %, average serum glucose on arrival is 17.2 ± 11.6 mmol/L. Time in range on 14th day 66,2 ± 16.9% higher than the 1st day 55.1 ± 29.0% (p=0.03). CGM can detect more hypoglycemia events than point-of-care capillary blood glucose (34.2% versus 17.2%). Adverse reaction rate is 3.4% only. Conclusion: Continuous glucose monitoring is not only useful in controlling blood glucose level but also in detecting more hypoglycemia events than point-of-care capillary blood glucose.